Completed PHASE2 INTERVENTIONAL 1-arm NCT00856323

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM

Sponsor: Friends Research Institute, Inc.

Conditions Amphetamine-Related Disorders HIV HIV Infections

Interventions CM Truvada

Updated 6 times since 2017 Last updated: Aug 12, 2016 Started: Jan 31, 2009 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Amphetamine-Related Disorders and HIV and is currently completed. Friends Research Institute, Inc. leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Friends Research Institute, Inc.
University of California, Los Angeles

Data source: Friends Research Institute, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States